{"protocolSection": {"identificationModule": {"nctId": "NCT01890148", "orgStudyIdInfo": {"id": "D3551C00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069", "officialTitle": "An Explorative Investigation to Study the Relationship and Distribution of Neutrophils in Bronchial Mucosal Tissue, Induced Sputum and Blood After Administration of 45 mg BD AZD 5069 for 4 Weeks to Patients With Moderate Persistent Neutrophilic Asthma"}, "statusModule": {"statusVerifiedDate": "2016-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03"}, "primaryCompletionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-06-17", "studyFirstSubmitQcDate": "2013-06-27", "studyFirstPostDateStruct": {"date": "2013-07-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-29", "resultsFirstSubmitQcDate": "2016-01-28", "resultsFirstPostDateStruct": {"date": "2016-02-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-01-28", "lastUpdatePostDateStruct": {"date": "2016-02-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Distribution of neutrophils in bronchial mucosal tissue in asthma patients before and after 4 wk treatment with AZD 5069", "detailedDescription": "The purpose is to investigate the bronchial tissue neutrophil counts and distribution in asthma patients after 4 week oral treatment with AZD 5069"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 13, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "oral BD administration of 45 mg AZD5069", "interventionNames": ["Drug: AZD5069"]}], "interventions": [{"type": "DRUG", "name": "AZD5069", "description": "oral BD administration of 45 mg AZD5069", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies", "description": "Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.\n\nFor semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.\n\nThe scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.", "timeFrame": "Baseline and Week 4"}, {"measure": "Summary for Change From Baseline Neutrophils in Sputum", "description": "Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.", "timeFrame": "Baseline, Day 8, Day 22 and Day29"}, {"measure": "Summary for Change From Baseline Neutrophil Cell Counts in Blood", "description": "Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value", "timeFrame": "Baseline, Day 2, Day 8, Day 15, Day 22, Day29 and Day 34"}], "secondaryOutcomes": [{"measure": "Summary for Change From Baseline for IL-8 by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "timeFrame": "Baseline and Day 29"}, {"measure": "Summary for Change From Baseline for GRO-alpha by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "timeFrame": "Baseline and Day 29"}, {"measure": "Summary for Change From Baseline for MMP-9 by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "timeFrame": "Baseline and Day 29"}, {"measure": "Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)"}, {"measure": "Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)"}, {"measure": "Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)"}, {"measure": "Number of Adverse Events", "description": "Summary of number of adverse events (safety set)", "timeFrame": "Up to 40 days"}, {"measure": "Number of Participants With Adverse Events", "description": "Summary of number of participants with adverse events (safety set)", "timeFrame": "Up to 40 days"}, {"measure": "Summary Statistics for Patient Diary Variables (Day Time)", "description": "Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).\n\nThe screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.\n\nOne participant left the study on day 2, due to adverse event.", "timeFrame": "Up to 44 days"}, {"measure": "Summary Statistics for Patient Diary Variables (Night Time)", "description": "Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).\n\nThe screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.\n\nOne participant left the study on day 2, due to adverse event.", "timeFrame": "Up to 44 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female patients of Caucasian origin, aged between 18 to 65 years, inclusive, at the time informed consent is obtained.\n2. Physician based (according to GINA 2011) diagnosis of asthma for at least 6 months prior to the date informed consent is obtained and confirmed by 1 of the detailed respiratory criteria stated in the CSP\n3. Morning prebronchodilator (ie, after abstinence from short-acting and long-acting \u00df-agonist treatment for \u2265 6 and \u2265 12 hours, respectively) FEV1 of \u226570% of predicted normal (PN) for age, sex and height at enrolment\n4. Increased number of neutrophils in induced sputum samples at baseline, with a relative neutrophil count of \u2265 50% of total sputum cell count\n5. Physician prescribed daily use of medium or high dose ICS (\u2265 fluticasone 250 \u03bcg to \u2264 1.000 \u00b5g or the equivalent daily, as defined in GINA 2011; see CSP Appendix E) plus LABA.\n\nExclusion Criteria:\n\n1. History of clinically relevant allergies or idiosyncrasies to AZD5069 or other investigational CXCR2 antagonists, or any inactive ingredient(s) of the IMP, or tool-substances (eg, salbutamol, local anaesthetics) used for the purpose of this study\n2. History of severe asthma exacerbation requiring hospitalization within the last 12 months before screening.\n3. Asthma exacerbation requiring a treatment course of systemic (ie, oral or parenteral) corticosteroids within the 3 months before screening or \u2265 3 courses within the last 12 months before screening.\n4. Moderate to severe airflow limitation (FEV1 \\<70% PN)\n5. Any chronic lower respiratory disease other than asthma (see CSP for details) that, as judged by the Investigator or Medical Monitor, would interfere with the evaluation of the IMP or interpretation of patient safety or study results.\n\n   -", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kai Richter, MSD", "affiliation": "Astrazeneca Sweden", "role": "STUDY_DIRECTOR"}, {"name": "Klaus F Rabe, MD", "affiliation": "Lung Clinic Grosshansdorf Germany", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Grosshansdorf", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Thirteen patients were screened; 8 patients were screening failures, 5 patients were enrolled in the study and received treatment with AZD5069.\n\nFirst patient enrolled: 11 March 2014. Last patient completed: 18 August 2014.", "groups": [{"id": "FG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.8", "spread": "10.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies", "description": "Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.\n\nFor semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.\n\nThe scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.", "populationDescription": "PD analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.21", "spread": "0.54"}]}]}]}, {"type": "PRIMARY", "title": "Summary for Change From Baseline Neutrophils in Sputum", "description": "Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.", "populationDescription": "PD analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline, Day 8, Day 22 and Day29", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.294", "spread": "3.062"}]}]}, {"title": "Day 22", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.670", "spread": "3.751"}]}]}, {"title": "Day 29", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.849", "spread": "1.861"}]}]}]}, {"type": "PRIMARY", "title": "Summary for Change From Baseline Neutrophil Cell Counts in Blood", "description": "Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value", "populationDescription": "PD Analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline, Day 2, Day 8, Day 15, Day 22, Day29 and Day 34", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.517", "spread": "0.420"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.494", "spread": "0.559"}]}]}, {"title": "Day 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.985", "spread": "0.425"}]}]}, {"title": "Day 22", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.658", "spread": "0.237"}]}]}, {"title": "Day 29", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.178", "spread": "1.375"}]}]}, {"title": "Day 34", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.306", "spread": "0.200"}]}]}]}, {"type": "SECONDARY", "title": "Summary for Change From Baseline for IL-8 by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "populationDescription": "PD analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline and Day 29", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "IL-8 in Serum", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.88", "spread": "34.13"}]}]}, {"title": "IL-8 in Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "5780.75", "spread": "3763.83"}]}]}]}, {"type": "SECONDARY", "title": "Summary for Change From Baseline for GRO-alpha by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "populationDescription": "PD analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline and Day 29", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "GRO-alpha in Serum", "categories": [{"measurements": [{"groupId": "OG000", "value": "179.75", "spread": "98.20"}]}]}, {"title": "GRO-alpha in Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "7352.50", "spread": "22373.99"}]}]}]}, {"type": "SECONDARY", "title": "Summary for Change From Baseline for MMP-9 by Type of Sample", "description": "Change from baseline reflects the Day 29 value minus the baseline value.", "populationDescription": "PD analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Baseline and Day 29", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "MMP-9 in Serum", "categories": [{"measurements": [{"groupId": "OG000", "value": "-157.75", "spread": "289.76"}]}]}, {"title": "MMP-9 in Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "-80.75", "spread": "178.55"}]}]}]}, {"type": "SECONDARY", "title": "Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "h*nmol/L", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8571.72", "spread": "2421.99"}]}]}]}, {"type": "SECONDARY", "title": "Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "466.92", "spread": "272.3"}]}]}]}, {"type": "SECONDARY", "title": "Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)", "description": "Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).\n\nPlasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3565.76", "spread": "762.84"}]}]}]}, {"type": "SECONDARY", "title": "Number of Adverse Events", "description": "Summary of number of adverse events (safety set)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "adverse events", "timeFrame": "Up to 40 days", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Total number of unique AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Total number of AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Total number of SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events", "description": "Summary of number of participants with adverse events (safety set)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 40 days", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Total number of subjects with at least one AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Number of subjects withdrawn from study due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Summary Statistics for Patient Diary Variables (Day Time)", "description": "Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).\n\nThe screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.\n\nOne participant left the study on day 2, due to adverse event.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Observations", "timeFrame": "Up to 44 days", "typeUnitsAnalyzed": "Observation", "denomUnitsSelected": "Participants", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}, {"units": "Observation", "counts": [{"groupId": "OG000", "value": "197"}]}], "classes": [{"title": "Obs. with No asthma symptoms (Screening; n=55)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Obs. with No asthma symptoms (Period1; n=71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Obs. with No asthma symptoms (Period2; n=71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Summary Statistics for Patient Diary Variables (Night Time)", "description": "Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).\n\nThe screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.\n\nOne participant left the study on day 2, due to adverse event.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Observations", "timeFrame": "Up to 44 days", "typeUnitsAnalyzed": "observations", "denomUnitsSelected": "Participants", "groups": [{"id": "OG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}, {"units": "observations", "counts": [{"groupId": "OG000", "value": "191"}]}], "classes": [{"title": "Obs. with No asthma symptoms (Screening; n=52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Obs. with No asthma symptoms (Period1; n=69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Obs. with No asthma symptoms (Period2; n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "AZD5069", "description": "AZD5069 45mg oral twice daily (BID)", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 4, "otherNumAtRisk": 5}], "otherEvents": [{"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Obstructive airways", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 5}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}]}, {"term": "Neutropil count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Larsson, Bengt", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com", "phone": "+46 (0) 317064277"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}